Located in Shangdong Mingshui Development Zone in China, its production site offers Recombinant Human Erythropoietin Injection(EPO)ã??Recombinant Human Granulocyte Colony-stimulating Factor Injection(rh-G-CSF)Filgrastimã??and Combined Clostridium Butyricum and Bifidobacterium Powders, Live for clinical and commercial use. Its workshop for genetically engineered drugs has area of 1, 500 square meters, and workshop for micro-ecological drugs covers 2, 000 square meters. Both workshops have passed Chinaâ??s GMP certification. The company plans to construct new factory buildings to improve production capacity and meet increasing market demands.The company develops recombinant genetic biological drugs and micro-ecological preparation, to serve the clinical treatment needs of kidney diseases, tumor, and gastrointestinal diseases. It has become a leading player in Chinaâ??s biopharmaceutical industry after more than 10 years of development.